CA2546730C - A method for the treatment of malignant diseases by inhibiting nucleolin - Google Patents

A method for the treatment of malignant diseases by inhibiting nucleolin Download PDF

Info

Publication number
CA2546730C
CA2546730C CA2546730A CA2546730A CA2546730C CA 2546730 C CA2546730 C CA 2546730C CA 2546730 A CA2546730 A CA 2546730A CA 2546730 A CA2546730 A CA 2546730A CA 2546730 C CA2546730 C CA 2546730C
Authority
CA
Canada
Prior art keywords
nucleolin
antibody
use according
hydrochloride
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2546730A
Other languages
English (en)
French (fr)
Other versions
CA2546730A1 (en
Inventor
Paula J. Bates
Donald M. Miller
John O. Trent
Xiaohua Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Louisville Research Foundation ULRF
Original Assignee
University of Louisville Research Foundation ULRF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Louisville Research Foundation ULRF filed Critical University of Louisville Research Foundation ULRF
Publication of CA2546730A1 publication Critical patent/CA2546730A1/en
Application granted granted Critical
Publication of CA2546730C publication Critical patent/CA2546730C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
CA2546730A 2003-10-09 2004-10-08 A method for the treatment of malignant diseases by inhibiting nucleolin Expired - Fee Related CA2546730C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/683,480 2003-10-09
US10/683,480 US7357928B2 (en) 2002-04-08 2003-10-09 Method for the diagnosis and prognosis of malignant diseases
PCT/US2004/033174 WO2005035579A1 (en) 2003-10-09 2004-10-08 A method for the treatment of maligant diseases by inhibiting nucleolin

Publications (2)

Publication Number Publication Date
CA2546730A1 CA2546730A1 (en) 2005-04-21
CA2546730C true CA2546730C (en) 2017-03-21

Family

ID=34435395

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2546730A Expired - Fee Related CA2546730C (en) 2003-10-09 2004-10-08 A method for the treatment of malignant diseases by inhibiting nucleolin

Country Status (7)

Country Link
US (4) US7357928B2 (enExample)
EP (1) EP1687337B1 (enExample)
JP (1) JP2008502584A (enExample)
AU (1) AU2004279837B2 (enExample)
CA (1) CA2546730C (enExample)
ES (1) ES2473598T3 (enExample)
WO (1) WO2005035579A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960540B2 (en) * 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US20080318889A1 (en) * 1999-04-08 2008-12-25 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US8114850B2 (en) * 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US20110178161A1 (en) * 1999-04-08 2011-07-21 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
PT1181304E (pt) * 1999-04-08 2008-01-23 Antisoma Res Ltd Actividade antiproliferativa de oligonucleótidos ricos em g e método de utilização dos mesmos para ligação a nucleolina
US20080318890A1 (en) * 1999-04-08 2008-12-25 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US7357928B2 (en) 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
US7541150B2 (en) * 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
CA2489520A1 (en) * 2002-06-26 2004-01-08 University Of Louisville Research Foundation, Inc. A method for the detection of apoptosis
US7831293B2 (en) * 2005-05-10 2010-11-09 Advanced Clinical Solutions, Inc. Method of defining a biological target for treatment
CN1862258B (zh) * 2005-05-12 2012-05-30 清华大学 核仁素辅助的癌症诊断与治疗方法
FR2900341B1 (fr) * 2006-04-27 2012-09-14 Centre Nat Rech Scient Utilisation de ligands synthetiques multivalents de la nucleoline de surface pour le traitement du cancer
WO2007137000A2 (en) 2006-05-16 2007-11-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Combination cancer chemotherapy
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
EP2222846B1 (en) 2007-08-10 2017-05-03 Protelix, Inc. Universal fibronectin type iii binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
ATE487487T1 (de) * 2007-09-04 2010-11-15 Inst Nat Sante Rech Med Verwendung von verbindungen, die die ef-tu- nucleolin wechselwirkung vehindern, zur verhinderung oder behandlung von tularämie
US20090131351A1 (en) * 2007-11-16 2009-05-21 Antisoma Research Limited Methods, compositions, and kits for modulating tumor cell proliferation
US20090226914A1 (en) * 2007-12-31 2009-09-10 Bates Paula J Methods and products to target, capture and characterize stem cells
EP2268284A2 (en) * 2008-02-05 2011-01-05 Antisoma Research Limited Use of g-rich oligonucleotides for treating neoplastic diseases
CN102037005B (zh) 2008-05-22 2017-03-29 国家科学研究中心 改善治疗功效的新光学纯化合物
WO2010017443A2 (en) * 2008-08-07 2010-02-11 Da Zen Group, Llc Anti-beta-2-microglobulin agents and the use thereof
KR100998365B1 (ko) * 2009-06-29 2010-12-06 압타바이오 주식회사 치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체
US8737715B2 (en) * 2009-07-13 2014-05-27 H. Lee Moffitt Cancer And Research Institute, Inc. Methods and apparatus for diagnosis and/or prognosis of cancer
CN102770529B (zh) * 2009-11-17 2018-06-05 Musc研究发展基金会 针对人核仁素的人单克隆抗体
WO2011103407A1 (en) * 2010-02-19 2011-08-25 The Ohio State University Primers and methods for nucleic acid amplification
US10030045B2 (en) * 2010-02-19 2018-07-24 Ohio State Innovation Foundation Primers and methods for nucleic acid amplification
WO2011109677A2 (en) * 2010-03-04 2011-09-09 University Of Louisville Research Foundation, Inc. Methods of increasing macropinocytosis in cancer cells
AU2011311665A1 (en) 2010-10-04 2013-05-02 Centre National De La Recherche Scientifique (Cnrs) Compositions comprising multivalent synthetic ligands of surface nucleolin and glycosaminoglycans
ES2572915T3 (es) 2011-06-02 2016-06-03 The University Of Louisville Research Foundation, Inc. Nanopartículas conjugadas a un agente antinucleolina
JP6301258B2 (ja) * 2011-11-03 2018-03-28 トライパス イメージング インコーポレイテッド 免疫染色試料を調製するための方法および構成物
WO2014187856A1 (en) * 2013-05-21 2014-11-27 Deutsches Krebsforschungszentrum Nucleoli disorganisation by knocking down specific alu-repeat containing rna sequences
WO2016179394A1 (en) 2015-05-05 2016-11-10 Malik Mohammad Tariq Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
CN106405084A (zh) * 2015-07-31 2017-02-15 复旦大学附属华山医院 核仁素在制备肠癌诊断试剂和治疗药物中的应用
CN106405096A (zh) * 2015-07-31 2017-02-15 复旦大学附属华山医院 核仁素在制备胃癌诊断试剂和治疗药物中的应用
JP7157981B2 (ja) * 2016-03-07 2022-10-21 チャールストンファーマ， エルエルシー 抗ヌクレオリン抗体
US20170338925A1 (en) * 2016-05-20 2017-11-23 National Taiwan University Scheduling method of communication system using directional reference signals and related apparatuses using the same
US11339396B2 (en) 2016-06-08 2022-05-24 President And Fellows Of Harvard College Engineered viral vector reduces induction of inflammatory and immune responses
WO2018026958A1 (en) 2016-08-02 2018-02-08 The University Of Louisville Research Foundation, Inc. Targeted nanodroplet emulsions for treating cancer
EP3600420A4 (en) * 2017-03-20 2020-12-23 Cancer Therapeutics Laboratories, Inc. TUMOR NECROSIS COMPOSITIONS AND METHODS
KR20200085812A (ko) 2017-11-08 2020-07-15 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 바이러스 벡터-유도된 염증 반응을 억제하기 위한 조성물 및 방법
WO2021050779A2 (en) 2019-09-10 2021-03-18 University Of Louisville Research Foundation, Inc. Anti-nucleolin agent-peg-conjugated nanoparticles
AR120886A1 (es) * 2019-12-24 2022-03-30 Dizal Jiangsu Pharmaceutical Co Ltd Anticuerpos anti-fgfr2b
WO2021202425A1 (en) 2020-03-28 2021-10-07 University Of Louisville Research Foundation, Inc. Methods of inhibiting or treating coronavirus infection, and methods for delivering an anti-nucleolin agent
EP4148132A4 (en) * 2020-05-07 2024-07-03 Interoligo Corporation NOVEL NUCLEIC ACID LIGAND AND ITS IDENTIFICATION METHOD

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4474892A (en) * 1983-02-16 1984-10-02 Board Of Trustees Of The Leland Stanford Junior University Two-site immunoassays using monoclonal antibodies of different classes or subclasses and test kits for performing same
US5169774A (en) * 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US4665897A (en) * 1984-05-25 1987-05-19 Lemelson Jerome H Composition and method for detecting and treating cancer
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5223427A (en) 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5192660A (en) * 1989-04-24 1993-03-09 The United States Of America As Represented By The Department Of Health And Human Services ELISA methods for the determination of human platelet derived growth factor (PDGF) dimer forms present in human tissues and fluids
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
AU635008B2 (en) * 1989-12-13 1993-03-11 Genelabs Diagnostics Pte Ltd Analytical apparatus and method for automated blot assay
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5736348A (en) * 1990-11-28 1998-04-07 Fundacao Oswaldo Cruz (Fiocruz) Method for the immunological diagnosis of Chagas' Disease using recombinant antigens
JPH05244988A (ja) 1992-03-04 1993-09-24 Green Cross Corp:The 抗組織因子モノクローナル抗体、及びこれによる免疫抑制剤
PT744958E (pt) 1994-01-31 2003-11-28 Univ Boston Bancos de anticorpos policlonais
JPH07242566A (ja) 1994-03-01 1995-09-19 Kirin Brewery Co Ltd 免疫抑制剤
US5691447A (en) * 1995-03-24 1997-11-25 Tanox Biosystems, Inc. GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies
US6096532A (en) * 1995-06-07 2000-08-01 Aastrom Biosciences, Inc. Processor apparatus for use in a system for maintaining and growing biological cells
EP0883344B2 (en) 1995-12-15 2010-06-09 VIRxSYS Corporation Therapeutic molecules generated by trans-splicing
US6048703A (en) * 1996-11-15 2000-04-11 Cephalon, Inc. Methods for detecting cell apoptosis
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
EP1007669A1 (en) 1997-03-12 2000-06-14 Institut Pasteur A novel cell surface receptor for hiv retroviruses, therapeutic and diagnostic uses
US6291643B1 (en) * 1997-06-05 2001-09-18 Board Of Reports, The University Of Texas System Apaf-1 an activator of caspase-3
EP0985039B1 (en) * 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6339075B1 (en) * 1997-06-30 2002-01-15 The University Of British Columbia Use of dextran and other polysaccharides to improve mucus clearance
AU6053898A (en) 1997-08-04 1999-02-22 Burnham Institute, The A cell-free system of mitochondria-dependent apoptosis, and methods of use ther eof
US6325785B1 (en) * 1997-08-14 2001-12-04 Sherwood Services Ag Sputum trap manifold with nested caps
US5925334A (en) * 1997-08-27 1999-07-20 Rubin; Bruce K. Use of surface active agents to promote mucus clearance
US5932475A (en) * 1997-12-12 1999-08-03 Incyte Pharmaceuticals, Inc. Human nucleolin-like protein
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO1999053057A1 (en) * 1998-04-10 1999-10-21 Chugai Research Institute For Molecular Medicine, Inc. Protein and gene participating in the differentiation of immortalized cells
US6306404B1 (en) * 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
DE69937835T2 (de) * 1998-09-24 2009-01-02 Promega Corp., Madison Antikörper für apoptosemarker und anwendungsverfahren
PT1181304E (pt) 1999-04-08 2008-01-23 Antisoma Res Ltd Actividade antiproliferativa de oligonucleótidos ricos em g e método de utilização dos mesmos para ligação a nucleolina
EP1173486A1 (en) 1999-04-15 2002-01-23 Merck Frosst Canada & Co. Antibodies that recognize app cleaved by caspases and methods of use
US6165786A (en) * 1999-11-03 2000-12-26 Isis Pharmaceuticals, Inc. Antisense modulation of nucleolin expression
ATE365327T1 (de) 1999-11-08 2007-07-15 Eisai Co Ltd Verfahren zum nachweis von zelltod mittels cytochrom c.
JP2001213804A (ja) 2000-01-31 2001-08-07 Chugai Pharmaceut Co Ltd 抗組織因子抗体の複合体
WO2001068836A2 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
WO2001091771A2 (en) 2000-06-01 2001-12-06 Theralife, Inc. Compositions for treating back and leg discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins
EP1286693A4 (en) 2000-06-02 2005-07-13 Univ Connecticut Health Ct COMPLEXES OF ALPHA (2) MACROGLOBULIN AND ANTIGENIC MOLECULES FOR USE IN IMMUNOTHERAPY
US20020028488A1 (en) * 2000-06-19 2002-03-07 Sujay Singh Transgenic avian species for making human and chimeric antibodies
DE10037861A1 (de) 2000-08-01 2002-02-14 Max Delbrueck Centrum Mittel zur Therapie maligner Erkrankungen
WO2002012437A2 (en) 2000-08-03 2002-02-14 Schooten Wim Van Production of humanized antibodies in transgenic animals
CZ302719B6 (cs) 2000-12-01 2011-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
DE60208562T2 (de) 2001-07-16 2006-11-09 Arla Foods Amba Verfahren zur herstellung von tagatose
AU2002362436A1 (en) 2001-10-03 2003-04-14 Rigel Pharmaceuticals, Inc. Modulators of lymphocyte activation and migration
AU2003228431A1 (en) * 2002-04-05 2003-10-27 The Burnham Institute Hmgn2 peptides and related melecules that selectively home to tumor blood vessels and tumor cells
US7541150B2 (en) 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
US7357928B2 (en) 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
CA2489520A1 (en) * 2002-06-26 2004-01-08 University Of Louisville Research Foundation, Inc. A method for the detection of apoptosis
TW200504210A (en) * 2003-07-30 2005-02-01 Chin-Tarng Lin A nucleolin antisense inhibiting growth of cancer cell
US20050187176A1 (en) * 2003-10-10 2005-08-25 Bates Paula J. Method for inhibiting NF-kappa B signaling and use to treat or prevent human diseases
CN1862258B (zh) * 2005-05-12 2012-05-30 清华大学 核仁素辅助的癌症诊断与治疗方法
WO2007016466A2 (en) 2005-07-29 2007-02-08 Sloan-Kettering Institute For Cancer Research Single wall nanotube constructs and uses therefor
US20090226914A1 (en) * 2007-12-31 2009-09-10 Bates Paula J Methods and products to target, capture and characterize stem cells
JP2013508399A (ja) 2009-10-21 2013-03-07 ヘルス リサーチ インコーポレイテッド 腫瘍イメージングの増強用のｐａａナノ粒子
US20110111002A1 (en) 2009-11-12 2011-05-12 Calin Viorel Pop Transport and delivery of glutathione into human cells using gold nanoparticles
CN102770529B (zh) 2009-11-17 2018-06-05 Musc研究发展基金会 针对人核仁素的人单克隆抗体
WO2011119058A2 (en) 2010-03-22 2011-09-29 Universidade De Coimbra F3-peptide targeted lipid-based nanoparticles useful for the treatment of angiogenesis-dependent diseases
ES2572915T3 (es) 2011-06-02 2016-06-03 The University Of Louisville Research Foundation, Inc. Nanopartículas conjugadas a un agente antinucleolina
JP5244988B1 (ja) 2012-02-20 2013-07-24 浜松ホトニクス株式会社 濃度測定装置および濃度測定方法

Also Published As

Publication number Publication date
US8029784B2 (en) 2011-10-04
US20050053607A1 (en) 2005-03-10
US20090017009A1 (en) 2009-01-15
WO2005035579A1 (en) 2005-04-21
EP1687337A1 (en) 2006-08-09
US7357928B2 (en) 2008-04-15
AU2004279837B2 (en) 2010-04-01
US8586717B2 (en) 2013-11-19
US20140220013A1 (en) 2014-08-07
US20120014942A1 (en) 2012-01-19
ES2473598T3 (es) 2014-07-07
CA2546730A1 (en) 2005-04-21
EP1687337B1 (en) 2014-03-26
JP2008502584A (ja) 2008-01-31
AU2004279837A1 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
CA2546730C (en) A method for the treatment of malignant diseases by inhibiting nucleolin
EP1492440B1 (en) A new method for the diagnosis and prognosis of malignant diseases
JP6912538B2 (ja) 血中循環腫瘍細胞に関する方法およびアッセイ
US20110065121A1 (en) Method for the detection of apoptosis
JP2006526992A (ja) 癌を検出し、癌の進行をモニタリングする方法
MX2009000622A (es) Inhibidores de amigo-2-para tratar, diagnosticar o detectar cancer.
EP3361251A1 (en) Method for detecting cancer cells, reagent for introducing substance into cancer cells, and composition for treating cancer
JP2024056774A (ja) アネキシンａ１を介した心血管石灰化の阻害に関する方法および組成物
WO2014061419A1 (ja) 新規癌マーカーおよびその利用
US11022608B2 (en) Compositions and methods for detecting and treating pathological fibroblast cells
Sudiono et al. PCNA expression in epithelial linings of odontogenic cysts
US20110014231A1 (en) Anti-measles cancer immunotherapy
EP1862178A1 (en) Use of HLTF antibodies for diagnosis and treatment of cancer
Berens RAW 264.7 macrophages induce tumor-initiating behavior in metastatic but not nonmetastatic mammary carcinoma clones.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20201008

MKLA Lapsed

Effective date: 20201008